InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,183.60
(
0.08%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.29
(
0.19%
)
Bitcoin
66,130.06
(
-0.76%
)
Post# of 252218
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Whalatane

Send PM Follow Ignore
Followers 120
Posts 20600
Boards Moderated 0
Alias Born 06/13/2011

Whalatane

Member Level

Re: ciotera post# 246988

Wednesday, 05/17/2023 2:28:11 PM

Wednesday, May 17, 2023 2:28:11 PM

Post# of 252218
Cio / Dew Have either of you looked at OMER's Narsoplimab ( OMS721) for Iga Nephropathy
P3 9 mth data due Q3
Has FDA breakthrough therapy and Orphan designation
Re ARDX ..FDA going for 6 mth review vs 2 mth ...even tho drug is currently on the market as IBSRELA for IBS-C . I'm wondering if they want more data on hyperkalemia in these patients as I saw that noted that in their IBSRELA PDF
Appreciate any thought you two ( or others here ) have on OMER

Kiwi
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up